Q-Med: Invitation to Press and Analyst Briefing on the Year-End Report

Q-Med (STO:QMED):

Bengt Agerup, CEO will present the company and comment on the report.

Moderator: Martin Sikorski, Cheuvreux.

To participate, please register in one of the following ways: at www.financialhearings.com, or mail hearings@financialhearings.com or by phone + 46(0) 8 411 43 80.

Wednesday's presentation can also be followed live by telephone conference, which is accessible by dialling + 44 (0) 20 8817 9301, confirmation code: 155 3458 or Web Cast Live at. www.financialhearings.com or www.q-med.com. The slide presentation will be available at www.q-med.com, on Wednesday, February 13 at the latest 10.00 a.m.

Q-Med's year-end report will be published around 08:00 a.m Wednesday, February 13.

Financial information from Q-Med during Year 2008:

29 April Interim Report January - March 2008 29 April Annual General Meeting 24 July Interim Report January - June 2008 24 October Interim Report January - September 2008

Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHA(TM), for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: Restylane(R) for filling lines and folds, contouring and creating volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the treatment of osteoarthritis of the hip and knee joints, Deflux(TM) for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, Zuidex(TM) for the treatment of stress urinary incontinence in women, and Solesta(TM) for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.

Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882. Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Web: www.q-med.com.

In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc.

This information was brought to you by Cision http://newsroom.cision.com